Loading presentation...

Present Remotely

Send the link below via email or IM

Copy

Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.

DeleteCancel

Make your likes visible on Facebook?

Connect your Facebook account to Prezi and let your likes appear on your timeline.
You can change this under Settings & Account at any time.

No, thanks

Nanomedicine: Ligands in cancer therapeutics

No description
by

Natalia Tomasova

on 4 December 2013

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Nanomedicine: Ligands in cancer therapeutics

Targeting ligands
1.Monoclonal antibodies
2.Aptamers
3.Oligopeptides
4.Vitamins and sugars

Nanomedicine: Ligands in cancer therapeutics
Tumour-based design
1.enhanced permeability and retention (EPR) effect
2.lower tumor extracellular pH
3.tumor-specific antigens

All of these characteristics were utilised in the follwing ligands

Target driven nanoparticles


+
use in clinic, specificity, NP conjugation
-
large complex,expensive,immunogenicity,increased size

Monoclonal antibodies
oligonucleotides (DNA RNA)
+ in vitro selection
cheaper
anytarget
improved targetting
-
Less established
negatively charged

Aptamers
+
Deeper penetration in dense tumours,
lower toxicity,
ideal in tumour growth
cheapest
easier and specific conjugation
Vitamins
References and additional sources
1. Nanodelivery Strategies in Cancer Chemotherapy
Biological Rationale and Pharmaceutical Perspectives
George Mattheolabakis, Basil Rigas, Panayiotis P Constantinides
Nanomedicine. 2012;7(10):1577-1590.
2.Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
3.Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 59(6), 491–504 (2007).
4.Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60(16), 4440–4445 (2000).
5.Aluri S, Janib SM, Mackay JA. Environmentally responsive peptides as anticancer drug carriers. Adv. Drug Deliv. Rev. 61(11), 940–952 (2009).
6.Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94(10), 2135–2146 (2005).

Nanodelivery Strategies in Cancer Chemotherapy
Biological Rationale and Pharmaceutical Perspectives
George Mattheolabakis, Basil Rigas, Panayiotis P Constantinides
Nanomedicine. 2012;7(10):1577-1590.
Nanodelivery Strategies in Cancer Chemotherapy
Biological Rationale and Pharmaceutical Perspectives
George Mattheolabakis, Basil Rigas, Panayiotis P Constantinides
Nanomedicine. 2012;7(10):1577-1590.
Full transcript